143 related articles for article (PubMed ID: 15089763)
1. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.
Nückel H; Frey UH; Dürig J; Dührsen U; Siffert W
Eur J Haematol; 2004 Apr; 72(4):259-63. PubMed ID: 15089763
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia.
Thunberg U; Tobin G; Johnson A; Söderberg O; Padyukov L; Hultdin M; Klareskog L; Enblad G; Sundström C; Roos G; Rosenquist R
Lancet; 2002 Dec; 360(9349):1935-9. PubMed ID: 12493261
[TBL] [Abstract][Full Text] [Related]
3. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12.
Zhang LY; Ibbotson RE; Orchard JA; Gardiner AC; Seear RV; Chase AJ; Oscier DG; Cross NC
Leukemia; 2003 Nov; 17(11):2097-100. PubMed ID: 12931211
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
[TBL] [Abstract][Full Text] [Related]
5. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study.
Wiley JS; Dao-Ung LP; Gu BJ; Sluyter R; Shemon AN; Li C; Taper J; Gallo J; Manoharan A
Lancet; 2002 Mar; 359(9312):1114-9. PubMed ID: 11943260
[TBL] [Abstract][Full Text] [Related]
6. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
[TBL] [Abstract][Full Text] [Related]
7. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Dürig J; Nückel H; Cremer M; Führer A; Halfmeyer K; Fandrey J; Möröy T; Klein-Hitpass L; Dührsen U
Leukemia; 2003 Dec; 17(12):2426-34. PubMed ID: 14523469
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in the P2X7 gene and its association with susceptibility to tuberculosis.
Singla N; Gupta D; Joshi A; Batra N; Singh J
Int J Tuberc Lung Dis; 2012 Feb; 16(2):224-9. PubMed ID: 22137490
[TBL] [Abstract][Full Text] [Related]
9. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia.
Sellick GS; Rudd M; Eve P; Allinson R; Matutes E; Catovsky D; Houlston RS
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):1065-7. PubMed ID: 15184265
[TBL] [Abstract][Full Text] [Related]
10. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
[TBL] [Abstract][Full Text] [Related]
11. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the P2X7 1513A/C loss-of-function polymorphism to extrapulmonary tuberculosis susceptibility in Tunisian populations.
Ben-Selma W; Ben-Kahla I; Boukadida J; Harizi H
FEMS Immunol Med Microbiol; 2011 Oct; 63(1):65-72. PubMed ID: 21635566
[TBL] [Abstract][Full Text] [Related]
13. A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes.
Cabrini G; Falzoni S; Forchap SL; Pellegatti P; Balboni A; Agostini P; Cuneo A; Castoldi G; Baricordi OR; Di Virgilio F
J Immunol; 2005 Jul; 175(1):82-9. PubMed ID: 15972634
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Ibrahim S; Jilani I; O'Brien S; Rogers A; Manshouri T; Giles F; Faderl S; Thomas D; Kantarjian H; Keating M; Albitar M
Cancer; 2003 Apr; 97(8):1914-9. PubMed ID: 12673718
[TBL] [Abstract][Full Text] [Related]
15. The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia.
Boonstra JG; von't Veer MB; Gratama JW
J Biol Regul Homeost Agents; 2004; 18(3-4):340-6. PubMed ID: 15786702
[TBL] [Abstract][Full Text] [Related]
16. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.
Dürig J; Naschar M; Schmücker U; Renzing-Köhler K; Hölter T; Hüttmann A; Dührsen U
Leukemia; 2002 Jan; 16(1):30-5. PubMed ID: 11840260
[TBL] [Abstract][Full Text] [Related]
17. The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Hoy T; Milligan D; Bentley P; Fegan C
Br J Haematol; 2003 Oct; 123(1):66-71. PubMed ID: 14510944
[TBL] [Abstract][Full Text] [Related]
18. CD38 gene polymorphism and risk of chronic lymphocytic leukemia.
Abramenko IV; Bilous NI; Pleskach GV; Chumak AA; Kryachok IA; Martina ZV; Dyagil IS
Leuk Res; 2012 Oct; 36(10):1237-40. PubMed ID: 22721814
[TBL] [Abstract][Full Text] [Related]
19. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
[TBL] [Abstract][Full Text] [Related]
20. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
